Literature DB >> 8871677

Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway.

H Moriyama1, K Yokono, K Amano, M Nagata, Y Hasegawa, N Okamoto, K Tsukamoto, M Miki, R Yoneda, N Yagi, Y Tominaga, H Kikutani, K Hioki, K Okumura, H Yagita, M Kasuga.   

Abstract

The present study demonstrated that a short-term administration of mAbs against leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) at critical periods resulted in complete protection of autoimmune diabetes in non-obese diabetic (NOD) mice. When these mAbs were administered for only 6 days at 2 wk of age, neither diabetes nor insulitis was observed at 30 wk of age. It appears that the tolerance against beta cell Ag(s) was induced by this transient blockade of the LFA-1/ICAM-1 pathway. Protective suppressor activity was not enough to prevent diabetes because co-transfer of splenocytes from female NOD mice, which had received these mAbs at 2 wk of age, resulted in only a short delay of the diabetic onset caused by adoptive transfer of splenocytes from acutely diabetic NOD mice. Transfer of these splenocytes to young NOD mice could not also abrogate the spontaneous diabetes and insulitis. Furthermore, cyclophosphamide treatment could not abrogate the protection. When splenocytes from the treated NOD mice were transferred to NOD-SCID mice, none of the recipient mice developed significant insulitis and subsequent overt diabetes, suggesting the absence or the inactivation of diabetogenic effector T cells. However, splenic T cells from the insulitis-free NOD mice that had received the mAb treatment preserved proliferative responses to both islet cells and 65-kDa glutamic acid decarboxylase (GAD65) in vitro. These results suggest that a unique peripheral tolerance was induced by the transient blockade of the LFA-1/ICAM-1 pathway in an early age of NOD mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871677

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.

Authors:  Ekua W Brenu; Timothy J Bartley; Casey M Wright; Emma E Hamilton-Williams
Journal:  Immunol Cell Biol       Date:  2017-06-14       Impact factor: 5.126

3.  cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells.

Authors:  Chuda Chittasupho; Prakash Manikwar; Jeffrey P Krise; Teruna J Siahaan; Cory Berkland
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

4.  Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation.

Authors:  N A Turgeon; J G Avila; J A Cano; J J Hutchinson; I R Badell; A J Page; A B Adams; M H Sears; P H Bowen; A D Kirk; T C Pearson; C P Larsen
Journal:  Am J Transplant       Date:  2010-09       Impact factor: 8.086

Review 5.  Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.

Authors:  Prakash Manikwar; Paul Kiptoo; Ahmed H Badawi; Barlas Büyüktimkin; Teruna J Siahaan
Journal:  Med Res Rev       Date:  2011-03-23       Impact factor: 12.944

6.  Critical roles of CD30/CD30L interactions in murine autoimmune diabetes.

Authors:  S Chakrabarty; M Nagata; H Yasuda; L Wen; M Nakayama; S A Chowdhury; K Yamada; Z Jin; R Kotani; H Moriyama; O Shimozato; H Yagita; K Yokono
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 7.  Vaccine therapies for the prevention of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  Solution structure of a novel T-cell adhesion inhibitor derived from the fragment of ICAM-1 receptor: cyclo(1,8)-Cys-Pro-Arg-Gly-Gly-Ser-Val-Cys.

Authors:  Bimo A Tejo; Teruna J Siahaan
Journal:  Biopolymers       Date:  2009-08       Impact factor: 2.505

9.  Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery.

Authors:  Meagan E Anderson; Teruna J Siahaan
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

Review 10.  Dissecting autoimmune diabetes through genetic manipulation of non-obese diabetic mice.

Authors:  Y Yang; P Santamaria
Journal:  Diabetologia       Date:  2003-10-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.